leukemia research reports impact factor 2020

Leukemia Research Reports - Impact Score, Ranking, SJR, h-index, Citescore, Rating, Publisher, ISSN, and Other Important Details

Published By: Elsevier Ltd.

Abbreviation: Leuk. Res. Rep.

Impact Score The impact Score or journal impact score (JIS) is equivalent to Impact Factor. The impact factor (IF) or journal impact factor (JIF) of an academic journal is a scientometric index calculated by Clarivate that reflects the yearly mean number of citations of articles published in the last two years in a given journal, as indexed by Clarivate's Web of Science. On the other hand, Impact Score is based on Scopus data.

Important details.

About Leukemia Research Reports

Leukemia Research Reports is a journal published by Elsevier Ltd. . This journal covers the area[s] related to Hematology, Oncology, etc . The coverage history of this journal is as follows: 2012-2022. The rank of this journal is 14147 . This journal's impact score, h-index, and SJR are 1.01, 14, and 0.333, respectively. The ISSN of this journal is/are as follows: 22130489 . The best quartile of Leukemia Research Reports is Q3 . This journal has received a total of 108 citations during the last three years (Preceding 2022).

Leukemia Research Reports Impact Score 2022-2023

The impact score (IS), also denoted as the Journal impact score (JIS), of an academic journal is a measure of the yearly average number of citations to recent articles published in that journal. It is based on Scopus data.

Prediction of Leukemia Research Reports Impact Score 2023

Impact Score 2022 of Leukemia Research Reports is 1.01 . If a similar upward trend continues, IS may increase in 2023 as well.

Impact Score Graph

Check below the impact score trends of leukemia research reports. this is based on scopus data..

Leukemia Research Reports h-index

The h-index of Leukemia Research Reports is 14 . By definition of the h-index, this journal has at least 14 published articles with more than 14 citations.

What is h-index?

The h-index (also known as the Hirsch index or Hirsh index) is a scientometric parameter used to evaluate the scientific impact of the publications and journals. It is defined as the maximum value of h such that the given Journal has published at least h papers and each has at least h citations.

Leukemia Research Reports ISSN

The International Standard Serial Number (ISSN) of Leukemia Research Reports is/are as follows: 22130489 .

The ISSN is a unique 8-digit identifier for a specific publication like Magazine or Journal. The ISSN is used in the postal system and in the publishing world to identify the articles that are published in journals, magazines, newsletters, etc. This is the number assigned to your article by the publisher, and it is the one you will use to reference your article within the library catalogues.

ISSN code (also called as "ISSN structure" or "ISSN syntax") can be expressed as follows: NNNN-NNNC Here, N is in the set {0,1,2,3...,9}, a digit character, and C is in {0,1,2,3,...,9,X}

Leukemia Research Reports Ranking and SCImago Journal Rank (SJR)

SCImago Journal Rank is an indicator, which measures the scientific influence of journals. It considers the number of citations received by a journal and the importance of the journals from where these citations come.

Leukemia Research Reports Publisher

The publisher of Leukemia Research Reports is Elsevier Ltd. . The publishing house of this journal is located in the United Kingdom . Its coverage history is as follows: 2012-2022 .

Call For Papers (CFPs)

Please check the official website of this journal to find out the complete details and Call For Papers (CFPs).

Abbreviation

The International Organization for Standardization 4 (ISO 4) abbreviation of Leukemia Research Reports is Leuk. Res. Rep. . ISO 4 is an international standard which defines a uniform and consistent system for the abbreviation of serial publication titles, which are published regularly. The primary use of ISO 4 is to abbreviate or shorten the names of scientific journals using the technique of List of Title Word Abbreviations (LTWA).

As ISO 4 is an international standard, the abbreviation ('Leuk. Res. Rep.') can be used for citing, indexing, abstraction, and referencing purposes.

How to publish in Leukemia Research Reports

If your area of research or discipline is related to Hematology, Oncology, etc. , please check the journal's official website to understand the complete publication process.

Acceptance Rate

• Interest/demand of researchers/scientists for publishing in a specific journal/conference.
• The complexity of the peer review process and timeline.
• Time taken from draft submission to final publication.
• Number of submissions received and acceptance slots
• And Many More.

The simplest way to find out the acceptance rate or rejection rate of a Journal/Conference is to check with the journal's/conference's editorial team through emails or through the official website.

Frequently Asked Questions (FAQ)

What is the impact score of leukemia research reports.

The latest impact score of Leukemia Research Reports is 1.01. It is computed in the year 2023.

What is the h-index of Leukemia Research Reports?

The latest h-index of Leukemia Research Reports is 14. It is evaluated in the year 2023.

What is the SCImago Journal Rank (SJR) of Leukemia Research Reports?

The latest SCImago Journal Rank (SJR) of Leukemia Research Reports is 0.333. It is calculated in the year 2023.

What is the ranking of Leukemia Research Reports?

The latest ranking of Leukemia Research Reports is 14147. This ranking is among 27955 Journals, Conferences, and Book Series. It is computed in the year 2023.

Who is the publisher of Leukemia Research Reports?

Leukemia Research Reports is published by Elsevier Ltd.. The publication country of this journal is United Kingdom.

What is the abbreviation of Leukemia Research Reports?

This standard abbreviation of Leukemia Research Reports is Leuk. Res. Rep..

Is "Leukemia Research Reports" a Journal, Conference or Book Series?

Leukemia Research Reports is a journal published by Elsevier Ltd..

What is the scope of Leukemia Research Reports?

For detailed scope of Leukemia Research Reports, check the official website of this journal.

What is the ISSN of Leukemia Research Reports?

The International Standard Serial Number (ISSN) of Leukemia Research Reports is/are as follows: 22130489.

What is the best quartile for Leukemia Research Reports?

The best quartile for Leukemia Research Reports is Q3.

What is the coverage history of Leukemia Research Reports?

The coverage history of Leukemia Research Reports is as follows 2012-2022.

Credits and Sources

• Scimago Journal & Country Rank (SJR), https://www.scimagojr.com/
• Journal Impact Factor, https://clarivate.com/
• Issn.org, https://www.issn.org/
• Scopus, https://www.scopus.com/

Note: The impact score shown here is equivalent to the average number of times documents published in a journal/conference in the past two years have been cited in the current year (i.e., Cites / Doc. (2 years)). It is based on Scopus data and can be a little higher or different compared to the impact factor (IF) produced by Journal Citation Report. Please refer to the Web of Science data source to check the exact journal impact factor ™ (Thomson Reuters) metric.

Impact Score, SJR, h-Index, and Other Important metrics of These Journals, Conferences, and Book Series

Check complete list

Leukemia Research Reports Impact Score (IS) Trend

Top Journals/Conferences in Hematology

Top journals/conferences in oncology.

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

• View all journals
• Explore content
• About the journal
• Publish with us
• Sign up for alerts

Journal Information

Aims and Scope Leukemia  publishes high quality, peer reviewed research that covers all aspects of the research and treatment of leukemia and allied diseases. Studies of normal hemopoiesis are covered because of their comparative relevance. Topics of interest include oncogenes, growth factors, stem cells, leukemia genomics, cell cycle, signal transduction, molecular targets for therapy and more. We publish a range of content types including original research articles, reviews, letters, correspondence and comments that elaborate on significant advances in the field and cover topical issues.

Why Publish in Leukemia ?

• Ranked in the top quartile of journals worldwide in the fields of oncology and hematology , we publish high quality, peer reviewed original content across all aspects of the research and treatment of leukemia and allied diseases.  
• We provide wide exposure and high visibility for your publication through our nature.com platform. We also offer funder-compliant open access options .
• Leading voices in the field across the globe form our expert editorial team , providing attractive turnaround times from first decision to publication. 

Journal Metrics

Article metrics such as number of downloads, citations and online attention are available from each article page, and provide an overview of the attention received by a paper.

Citation Impact 2023

• Journal Impact Factor: 12.8
• 5-year Journal Impact Factor: 10.5
• Source Normalized Impact per Paper (SNIP): 2.441
• SCImago Journal Rank (SJR): 3.662
• Submission to first editorial decision (median days): 5
• Submission to acceptance (median days): 106
• Downloads: 2,535,447
• Altmetric mentions: 4,878

More about our metrics

Frequency 12 issues per year

Abstracted/indexed in: EBSCO Discovery Service Google Scholar OCLC Summon by ProQuest BIOSIS Current Contents/Life Sciences Science Citation Index Science Citation Index Expanded (SciSearch) SCOPUS EBSCO Academic Search EBSCO Advanced Placement Source EBSCO Biomedical Reference Collection EBSCO CINAHL EBSCO STM Source EBSCO TOC Premier INIS Atomindex

ISSN and eISSN International standard serial number (ISSN): 0887-6924 Electronic international standard serial number (eISSN): 1476-5551.

Newsfeeds Leukemia  now provides its latest table of contents as an RSS web feed. This allows users with an RSS reader to receive automatic updates whenever new content is added to these pages.

Receive  Leukemia 's current issue table of contents .

Quick links

• Explore articles by subject
• Guide to authors
• Editorial policies

Leukemia Research Reports

Volume 2 • Issue 2

• ISSN: 2213-0489

Editor-In-Chief: Marie-Christine Kyrtsonis

• Impact factor: 0.7
• Journal metrics

Official journal of the Myelodysplastic Syndromes Foundation.Leukemia Research Reports (LRR), a companion title to Leukemia Research, is a peer-reviewed publication devoted to the… Read more

Subscription options

Institutional subscription on sciencedirect.

Official journal of the Myelodysplastic Syndromes Foundation .

Leukemia Research Reports (LRR) , a companion title to Leukemia Research , is a peer-reviewed publication devoted to the rapid publication of short, high-quality papers related to a broad scope of therapeutic areas of hematology, including hematologic malignancies and other non-malignant diseases, such as:

Hematopoetic and stem cell transplantation;

Marrow and stem cell reconstitution;

Leukemic hemopoiesis;

Leukemias, lymphomas, multiple myelomas and other hematological malignancies;

Cell based therapies and treatment for cancer and immunotherapy for hematological malignancy.

The journal aims to publish manuscripts that provide guidance to clinicians around the world to provide education on best practices and clinical research; report cutting-edge translational science related to hematological malignancies; register important observations that significantly add to previously-reported novel observations; provide compelling illustrations of important clinical principles related to the care of patients; or foment the scientific discussion from an uncommon perspective.

All articles published in Leukemia Research Reports are peer-reviewed and indexed in PubMed/PubMed Central and Scopus . They are fully citable through digital object identifiers (DOI) and rapidly available online via ScienceDirect, the world's leading online content platform.

An official website of the United States government

The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

• Publications
• Account settings

Preview improvements coming to the PMC website in October 2024. Learn More or Try it out now .

• Advanced Search
• Journal List
• Leuk Res Rep
• v.1(1); 2012

Leukemia Research Reports : Guide for authors

Leukemia Research Reports is an open access, international journal which delivers timely information online to all health care professionals involved in basic and/or applied clinical research in leukemias, lymphomas, multiple myeloma and other hematologic malignancies. It does this by rapidly publishing a range of peer-reviewed short form papers, including brief communications, case reports, letters to the Editors, images, and debate articles. The Editors encourage the submission of articles relevant to normal and leukemic hemopoiesis, biochemistry, cell biology, immunology and molecular biology as well as epidemiologic and clinical studies. Leukemia Research Reports ' coverage encompasses the application of oncogenes, genomics (gene expression profiles and microRNAs), proteomics, growth factors, cell markers, cell cycle and differentiation agents, novel therapeutics and clinical trials in both the acute and chronic leukemias as well as the myelodysplastic syndromes. In addition articles are solicited on the rapidly growing specialty of marrow or stem cell reconstitution after high dose therapy with curative attempt in patients with a wide range of neoplasms.

Publishing policy —All articles will be peer reviewed and if accepted for publication in the Journal, Authors will be notified of this decision and at the same time requested to pay an Article Processing Fee of US$ 600/EUR 458/JPY 46,638 (exclusive of VAT/Sales Tax). Following payment of this fee, articles will be made universally available at no further charge through ScienceDirect and through the Journal's own website www.lrreports.com .

Submission of Manuscripts – All Manuscripts and Material should be submitted on-line via EES→ http://ees.elsevier.com/lrr/

Please refer to the ‘Tutorial for Authors’ located on the EES site for guidance on the electronic submission process.

All published papers containing research data are subject to peer-review. Submission of an article implies that the work described has not been published previously and will not be simultaneously submitted or published elsewhere (except in the form of an abstract or as part of a published lecture or academic thesis), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, without the written consent of the Publisher.

These guidelines generally follow the ‘Uniform Requirements for Manuscripts Submitted to Biomedical Journals’. The complete document appears at → http://www.icmje.org .

Submitting an Article —Articles should be submitted online at → http://ees.elsevier.com/lrr/ and the instructions on the site should be closely followed. Authors may submit manuscripts and track their progress to final decision.

Types of Contribution —All articles are limited by word count and the number of references. Word count limits do not include the abstract, references, acknowledgment, figures or tables, or their captions.

Brief Communications include an abstract; the total word count should not exceed 1200 words, a maximum of 10 references and up to 4 figures and/or tables.

Case Reports include an abstract; they should not exceed 1200 words, a maximum of 10 references and an optional 1–2 figures and/or tables.

Letters to the Editor should clearly indicate the purpose of the letter by a brief striking title; they should include an abstract and should not exceed 1200 words, up to 5 references and an optional 1–2 figures and/or tables.

Debate and Controversies —the journal welcomes opinion pieces on research and clinical topics in leukemia. Debate & Controversies articles should include an abstract, should not exceed 1200 words, plus a maximum of 5 references and 1 figure or table.

Images —authors are encouraged to submit images for publication. These should be accompanied by a title and a caption that explains the significance of the image. In addition to ‘still life ‘ images, authors may submit video files. For full details of artwork formats see below.

Meeting Perspectives are reports on one or several sessions of Congress, Workshops or Symposia (also closed ones). Such papers should not exceed 1200 words, 5 references and up to 2 figures and/or tables.

Comments on Published Papers are comments on a prior published paper. Mention the title in both the Cover Letter and the References. This paper does not have an abstract and should not exceed 1200 words; limit 3 references and optional 1–2 figures and/or tables. Comments that seek to address an error in a previous paper are exempt from the Article Processing Fee if accepted for publication.

Preparation of Manuscripts

1. Covering letter : This is a letter stating that you wish to submit your paper to Leukemia Research Reports . Please include the title, and signature of corresponding author. Also include details of any previous version.

2. All contributions must be 1.5 spaced except the references which are single spaced with a space between each reference.

3. Manuscripts submitted for publication should be written concisely and clearly. Manuscripts will only be accepted when they are written in an acceptable standard of English (American or British usage is accepted, but not a mixture of these). Authors whose native language is not English are strongly advised to have their manuscripts be checked by an English-speaking colleague prior to submission or to submit them for language editing (see below for more details). Either the Concise Oxford Dictionary or Webster's New International Dictionary may be used as a standard for English spelling.

4. The manuscript should be organized in the following sequence: All manuscripts must have a title page which is Page 1 of your manuscript. Note the Title should be clear, descriptive and less than 20 words long. Avoid non-specific phrases such as ‘A study of…’ or ‘The effects of…’. Do not give the title a numbered subtitle or series number.

The title page is the first page of the paper and must contain the following: title name of authors (listed as, first name last name academic degree then superscript the institutional code); institutional has superscript code (1, 2, 3,…), Department of…, institution, city and country; the Corresponding Author. Note : No positions like Dr., Professor, or Faculty of, we use academic degrees only.

Role of Corresponding Author : Please note there is only one corresponding author of the manuscript. The corresponding author is the one that submits the manuscript and is displayed on the Title Page of the manuscript. They have the duty to ensure that all of the named authors have seen and approved the original manuscript and subsequent revisions. Each author should have participated sufficiently in the work to take public responsibility for the content. The corresponding author should also ensure that those who have contributed to the research are acknowledged appropriately either as a co-author or in the Acknowledgments. In addition, the corresponding author has the prime responsibility for ensuring the paper is correctly prepared according to the Guide for Authors. Submitted manuscripts not complying with the Guide for Authors may be returned to the authors for revision.

Word Count : does not include the references, acknowledgment, figures and tables.

Abstract : The abstract should be clear, descriptive and less than 100 words.

Keywords —Keywords are index terms or descriptions for information retrieval systems, and a maximum of five should be provided. Words selected should reflect the essential topics of the article and may be taken from both the title and the text.

Abbreviations and units : Generally, avoid abbreviations in the Title and abbreviating single words. Otherwise explain all abbreviations at first mention in the abstract and text, except for: DNA, RNA, AIDS, and HIV. Standard SI abbreviations for units do not need to be spelled out.

Brief Communications should include an Introduction, Materials and Methods, Results and Discussion sections. Case Reports and Letters to the Editor do not need to include these divisions.

Introduction : This should give the reasons for doing the work. As this is a specialist journal a detailed review of the literature is not necessary. The introduction should preferably conclude with a final paragraph stating concisely and clearly the aims and objectives of the investigation.

Materials and Methods : A full technical description of a method should be given in detail only when the method is new.

Results : This need only report results of representative experiments illustrated by tables and figures. Use well-known statistical tests in preference to obscure ones. Consult a statistician or a statistics text for detailed advice.

Discussion (including Conclusions) : This section must not recapitulate results but should relate the authors' experiments to other work and give their conclusions, which may be given in a subsection headed after called Conclusions.

References : References are numbered. All publications cited in the text should be presented in a list of references following the text of the manuscript. In the text refer to references by a number in square brackets on the line (e.g. Since Peterson [1]), and the full reference should be given in a numerical list at the end of the paper. References should be given in the following form: 1. Latagliata R, Concetta Petti M, Mandelli F. Acute myeloid leukemia in the elderly: ‘per aspera ad astra’? Leukemia Res 1999;23:603–613. 2. Alfrey V. The isolation of subcellular components. In: Brachet J, Mirsky AE, editors. The cell, biochemistry, physiology, morphology I. New York: Academic Press, 1959. p. 200.

Note : Authors are strongly encouraged to check the accuracy of each reference against its original source. Work accepted for publication but not yet published should be referred to as ‘in press’. Authors should provide evidence (such as a copy of the letter of acceptance). References concerning unpublished data, theses, and ‘personal communications’ should not be cited in the reference list but may be mentioned in the text. Do not only put the first author et al. list all authors.

5. Acknowledgments should be organized in the following sequence.

Acknowledgments —All contributors who do not meet the criteria for authorship as defined above should be listed in an acknowledgments section. E.g. those who might be acknowledged include a person who provided purely technical help, writing assistance, or a department chair that provided only general support. Authors should disclose whether they had any writing assistance and identify the entity that paid for this assistance.

Role of the funding source— All sources of funding should be declared. Authors should declare the role of study sponsors, if any, in the study design, collection, analysis and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. If the study sponsors had no such involvement, the authors should so state.

Authors' Contributions —All authors should have made substantial contributions to the following: (1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data. (2) drafting the article or revising it critically for important intellectual content. (3) final approval of the version to be submitted. For authors we use initials and if there is more than one author that does the same function put them together. Note: If there is more than one author that contributed equally to the work it goes in this section not on the title page.

Conflict of Interest —All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. E.g. potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. If there no conflicts of interest exist this must be stated. Please see the Elsevier website for further information http://www.elsevier.com/wps/find/authorsview.authors/conflictsofinterest .

6. Figures and Figure Legends —Figures should be cited consecutively in the text. Full details for the electronic submission of artwork can be obtained from http://www.elsevier.com/artworkinstructions . All figures have to be uploaded in EES separately.

For further information on the preparation of electronic artwork, please see http://www.elsevier.com/artworkinstructions .

Type the figure legends in order in one word document and starting with the words figure legends; limit 40 words or less. Spacing is 1.5 and if more than one page put a page number in the footer.

7. Table and Table Legends —Tables should be cited consecutively in the text. Type tables on separate pages with a title. Avoid white spaces in the table by using footnotes, and ensure all symbols or abbreviation are explained. Take care to distinguish between ‘zero’ and ‘not done’ as an entry in the table. Tables are uploaded separately.

Type the table legends in order in one word document and starting with the words table legends. Spacing is 1.5 and if more than one page put a page number in the footer.

Footnotes : Footnotes should only be used to provide addresses of authors or to provide explanations essential to the understanding of Tables.

8. Supplementary Data —As Leukemia Research Reports focuses on short papers, Supplementary Data files are not accepted.

Ethics —Identifying information, including patients images, names, initials, or hospital numbers, should not be included in videos, recordings, written descriptions, photographs, and pedigrees unless the information is essential for scientific purposes and you have obtained written informed consent for publication in print and electronic form from the patient (or parent, guardian or next of kin where applicable). If such consent is made subject to any conditions, Elsevier must be made aware of all such conditions. Written consents must be provided to Elsevier on request.

Even where consent has been given, identifying details should be omitted if they are not essential. If identifying characteristics are altered to protect anonymity, such as in genetic pedigrees, authors should provide assurance that alterations do not distort scientific meaning and editors should so note.

If such consent has not been obtained, personal details of patients included in any part of the paper and in any supplementary materials (including all illustrations and videos) must be removed before submission.

Drug names —Use generic names for drugs. Commercial names may be included in parentheses at first mention in the text. Complicated drug names or regimens may be abbreviated, with the abbreviation in parentheses after first mention.

Revised Manuscript —All manuscripts are peer-reviewed. On receipt of the first decision letter authors should send their revised manuscript as soon as possible in order to ensure that the scientific content of their manuscript is timely and up to date.

The revised paper must be submitted without tracking or highlights and 1.5 spaced. A Revision Letter must contain detailed responses to the reviewers and indicate where in the letter you changed the text.

Author Names —This policy concerns the addition, deletion, or rearrangement of author names in the authorship of accepted manuscripts: Before the accepted manuscript is published in an online issue: Requests to add or remove an author, or to rearrange the author names, must be sent to the Journal Manager from the corresponding author of the accepted manuscript and must include the following: (a) the reason the name should be added or removed, or the author names rearranged and (b) written confirmation (e-mail, fax, and letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed. Requests that are not sent by the corresponding author will be forwarded by the Journal Manager to the corresponding author, who must follow the procedure as described above. Note that (1) Journal Managers will inform the Journal Editors of any such requests and (2) publication of the accepted manuscript in an online issue is suspended until authorship has been agreed. After the accepted manuscript is published in an online issue: Any requests to add, delete, or rearrange author names in an article published in an online issue will follow the same policies as noted above and result in a corrigendum.

Copyright —Upon acceptance of an article, authors will be asked to sign a Journal Publishing Agreement. This includes details of the rights that you retain as author (for more information on this and copyright see http://www.elsevier.com/wps/find/authorsview.authors/authorsrights ). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a Journal Publishing Agreement form. Following signature of this form and payment of the Author Fee, case reports will be made universally accessible through →ScienceDirect and through the Journal's own website, www.lrreports.com .

If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for use by authors in these cases; contact Elsevier s Rights Department, Philadelphia, PA, USA: Tel. (+1) 215 238 7869; Fax (+1) 215 238 2239; e-mail [email protected]. Requests may also be completed online via the Elsevier homepage ( http://www.elsevier.com/locate/permissions ).

Proofs —One set of page proofs in PDF format will be sent by e-mail to the corresponding author. Elsevier now sends PDF proofs which can be annotated; for this you will need to download Adobe Reader version 7 available free from → http://www.adobe.com/products/acrobat/readstep2.html . Instructions on how to annotate PDF files will accompany the proofs. The exact system requirements are given at the Adobe site: → http://www.adobe.com/products/acrobat/acrrsystemreqs.html#70win . If you do not wish to use the PDF annotations function, you may list the corrections (including replies to the Query Form) and return to Elsevier in an e-mail. Please list your corrections quoting line number. If, for any reason, this is not possible, then mark the corrections and any other comments (including replies to the Query Form) on a printout of your proof and return by fax, or scan the pages and e-mail, or by post.

Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. We will do everything possible to get your article published quickly and accurately. Therefore, it is important to ensure that all of your corrections are sent back to us in one communication: please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility. Note that Elsevier may proceed with the publication of your article if no response is received.

Language services —Authors who require information about language editing and copyediting services pre- and post-submission should visit → http://webshop.elsevier.com/languageservices or our customer support site at → http://support.elsevier.com for more information.

Enquiries —Authors can keep a track on the progress of their accepted article, and set up e-mail alerts informing them of changes to their manuscript's status, by using the ‘Track a Paper’ feature at: http://www.elsevier.com/trackarticle . For privacy, information on each article is password-protected. The author should key in the ‘Our Reference’ code (which is in the letter of acknowledgment sent by the publisher on receipt of the accepted article) and the name of the corresponding author. In case of problems or questions, authors may contact the Author Service Department, E-mail: [email protected]

Offprints —The corresponding author, at no cost, will be provided with a PDF file of the article via e-mail. The PDF file is a watermarked version of the published article and includes a cover sheet with the journal cover image and a disclaimer outlining the terms and conditions of use.

© 2012 Elsevier Ltd. All rights reserved —This journal and the individual contributions contained in it are protected under copyright by Elsevier Ltd. Please click on User Rights for a summary of how articles published in Leukemia Research Reports can be utilized.

Notice —No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.

Thank you for considering Leukemia Research Reports for your submission.

Leukemia Research

Subject Area and Category

• Cancer Research

Elsevier Ltd

Publication type

01452126, 18735835

Information

How to publish in this journal

[email protected]

The set of journals have been ranked according to their SJR and divided into four equal groups, four quartiles. Q1 (green) comprises the quarter of the journals with the highest values, Q2 (yellow) the second highest values, Q3 (orange) the third highest values and Q4 (red) the lowest values.

The SJR is a size-independent prestige indicator that ranks journals by their 'average prestige per article'. It is based on the idea that 'all citations are not created equal'. SJR is a measure of scientific influence of journals that accounts for both the number of citations received by a journal and the importance or prestige of the journals where such citations come from It measures the scientific influence of the average article in a journal, it expresses how central to the global scientific discussion an average article of the journal is.

Evolution of the number of published documents. All types of documents are considered, including citable and non citable documents.

This indicator counts the number of citations received by documents from a journal and divides them by the total number of documents published in that journal. The chart shows the evolution of the average number of times documents published in a journal in the past two, three and four years have been cited in the current year. The two years line is equivalent to journal impact factor ™ (Thomson Reuters) metric.

Evolution of the total number of citations and journal's self-citations received by a journal's published documents during the three previous years. Journal Self-citation is defined as the number of citation from a journal citing article to articles published by the same journal.

Evolution of the number of total citation per document and external citation per document (i.e. journal self-citations removed) received by a journal's published documents during the three previous years. External citations are calculated by subtracting the number of self-citations from the total number of citations received by the journal’s documents.

International Collaboration accounts for the articles that have been produced by researchers from several countries. The chart shows the ratio of a journal's documents signed by researchers from more than one country; that is including more than one country address.

Not every article in a journal is considered primary research and therefore "citable", this chart shows the ratio of a journal's articles including substantial research (research articles, conference papers and reviews) in three year windows vs. those documents other than research articles, reviews and conference papers.

Ratio of a journal's items, grouped in three years windows, that have been cited at least once vs. those not cited during the following year.

Evolution of the percentage of female authors.

Evolution of the number of documents cited by public policy documents according to Overton database.

Evoution of the number of documents related to Sustainable Development Goals defined by United Nations. Available from 2018 onwards.

Leave a comment

Name * Required

Email (will not be published) * Required

* Required Cancel

The users of Scimago Journal & Country Rank have the possibility to dialogue through comments linked to a specific journal. The purpose is to have a forum in which general doubts about the processes of publication in the journal, experiences and other issues derived from the publication of papers are resolved. For topics on particular articles, maintain the dialogue through the usual channels with your editor.

Follow us on @ScimagoJR Scimago Lab , Copyright 2007-2024. Data Source: Scopus®

Cookie settings

Cookie Policy

Legal Notice

Privacy Policy

• Editage One platform for all researcher needs
• Paperpal AI-powered academic writing assistant
• R Discovery Your #1 AI companion for literature search
• Mind the Graph AI tool for graphics, illustrations, and artwork
• [email protected]
• Request a callback

Researcher.Life is built on Editage's in-depth understanding of what researchers need during publication and beyond, accumulated over 20 years.

Leukemia Research Reports : Impact Factor & More

Check your submission readiness.

Find out how your manuscript stacks up against 24 technical compliance and 6 language quality checks.

Leukemia Research Reports Key Metrics

Topics covered on leukemia research reports, leukemia research reports journal specifications.

Indexed in the following public directories

Submissions Pack

One subscription packed with expert publication services and AI tools to get you published

Journal Selection Service

Benefit from our experts' recommendations of 3-5 best-suited journals, accompanied by a detailed Journal Selection report explaining the choices. Make informed decisions.

Journal Submission Service

Streamline your submission process with meticulous manuscript formatting to meet journal guidelines, crafting a tailored cover letter for the editor, and hassle-free account creation and submission

Bundle of AI tools for your research needs

Journal Finder, Paperpal, R Discovery, MindTheGraph and more

Buy now for a special Launch price!

Planning to publish in Leukemia Research Reports ?

Upload your Manuscript to get

• Degree of match
• Common matching concepts
• Additional journal recommendations

Recently Published Papers in Leukemia Research Reports

• Leukemia Research Reports
• 26 Jul 2024

Compare Similar Journals with Leukemia Research Reports

Annals of hematology, british journal of haematology, leukemia research, frontiers in oncology, journal of clinical oncology, international journal of hematology.

SJR Ranking, Topics covered, Indexing Database, Publication Review Time, Publication Type, Article Processing Charges & Recently Published papers

Get detailed Journal comparison report on your email by signing up

Check if your research matches the topics covered in Leukemia Research Reports?

Leukemia research reports scite analysis.

462 articles received 1.7K citations see all

• 56 Supporting
• 1,526 Mentioning
• 4 Contrasting

Leukemia Research Reports Editorial notices

• 1 Retractions
• 1 Withdrawals
• 0 Corrections
• 0 Expression of Concern

FAQs on Leukemia Research Reports

How many articles did leukemia research reports publish last year.

In 2023, Leukemia Research Reports publsihed 48 articles.

Who is the publisher of Leukemia Research Reports?

Elsevier is the publisher of Leukemia Research Reports.

Copyright 2024 Cactus Communications. All rights reserved.

Journal Abbreviation: LEUKEMIA Journal ISSN: 0887-6924

You may also be interested in the following journals

• ► Blood
• ► PLoS One
• ► Leukemia & Lymphoma
• ► Cancer Cell
• ► Cancer Research
• ► Leukemia Research
• ► Haematologica
• ► Science Translational Medicine
• ► Journal of Immunology
• ► Lancet Oncology

Top Journals in medicine

• New England Journal of Medicine
• Nature Reviews Drug Discovery
• Jama-Journal of The American Medical Association
• Nature Reviews Cancer
• Nature Reviews Immunology
• Lancet Oncology
• Nature Reviews Neuroscience
• Nature Medicine
• World Psychiatry
• Lancet Neurology
• Journal of Clinical Oncology

Journal Impact